Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 78Genitourinary 30Thoracic 11Dermatologic 9CNS 8Sarcoma 5Other hematologic neoplasm 3Tumor-Agnostic 2Other solid neoplasm 2Gynecologic 2Breast 2Other neoplasm 1

Conditions

Breast Neoplasms 2Pathologic Complete Response 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Vinblastine × Breast × Clear all
NCT02299999 2025-01-15

SAFIR02_Breast

UNICANCER

Phase 2 Active not recruiting
1,460 enrolled
Breast

Breast Neoplasms

NCT04781725 2021-11-17

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

Ottawa Hospital Research Institute

Phase 2 Unknown
90 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡